Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer (2013) 1.75

Predictive factors of Gleason score upgrading in localized and locally advanced prostate cancer diagnosed by prostate biopsy. Korean J Urol (2010) 1.01

Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy. BMC Urol (2014) 0.83

A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients. Chin J Cancer (2014) 0.83

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch (2015) 0.82

Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. Int J Clin Exp Pathol (2012) 0.79

Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study. Asian J Androl (2015) 0.77

A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients. World J Urol (2016) 0.77

Prostate cancer in 2010: GSU: misclassification or biological progression? Nat Rev Urol (2011) 0.75

Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. Oncotarget (2016) 0.75

Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer. Int Braz J Urol (2015) 0.75

Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Exp Biol Med (Maywood) (2014) 0.75

Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices. Adv Urol (2013) 0.75

Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis. World J Urol (2017) 0.75

Population-based study of grade progression in patients who harboured Gleason 3 + 3. World J Urol (2017) 0.75

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60

Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66

Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57

Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26

An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99

Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97

Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81

FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (2010) 2.79

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50

Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43

Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration (2005) 2.43

Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37

GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30

Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26

Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development (2006) 2.20

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13

The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13

Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11

Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08

High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06

Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03

Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01

Plasma vaporisation of the prostate: initial clinical results. Eur Urol (2009) 1.80

A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol (2009) 1.78

A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76

Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74

Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70

Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68

Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res (2008) 1.65

Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63

Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63

Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62

Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61

Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61

Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology (2009) 1.59

Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57

External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56

Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54

18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54

High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51

Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol (2011) 1.51

Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. Eur Urol (2009) 1.51

Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50

Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50

Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology (2010) 1.49

Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49

The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49

Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology (2012) 1.48

Non-bone-marrow-derived endothelial progenitor cells: what is their exact location? Circ Res (2007) 1.48

Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest (2010) 1.48

Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood (2005) 1.48

Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46

Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur Urol (2011) 1.46

Expression of guanylyl cyclase B in the human corpus cavernosum penis and the possible involvement of its ligand C-type natriuretic polypeptide in the induction of penile erection. J Urol (2003) 1.46

Postprostatectomy incontinence: all about diagnosis and management. Eur Urol (2008) 1.44

Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43